Medical Advocates
HIV/HCV Coinfection
 
Antiretroviral Drugs
 
HAART/ART: General Reports      
Abacavir                                       
Atazanavir                                    
Darunavir                                     
Didanosine
Efavirenz
Fosamprenavir
Lopinavir
Maraviroc
Nelfinavir		 Nevirapine
Raltegravir
Ritonavir
Stavudine
Tenofovir
Tenofovir
Tipranavir
Zidovudine
Peginterferons
 		  
HIV/HCV Main Page Main New/Newsworthy  Home Page
Last Update:  April 22, 2012  
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
HAART/ART General Reports
 

    Journal Papers, Abstracts, and Commentaries
 
 
A WEEK-IN-REVIEW FEATURED REPORT
HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.
Ingiliz P, Rockstroh JK
 Liver Int. 2012 Apr 17
 Abstract

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog
or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients.
Macías J, Neukam K, Mallolas J,  et al
HIV Clin Trials. 2012 Mar-Apr;13(2):61-9.
Abstract

Risk of elevated TC/HDL-C ratio after antiretroviral therapy in HIV/HCV patients.
Kakinami L, Block RC, Adams MJ,  et al
AIDS Res Hum Retroviruses. 2012 Mar.
 Abstract

HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
 Jones M, Núñez M.
Curr Opin HIV AIDS. 2011 Nov;6(6):546-52.
 Abstract

Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV
co-infected patients.
Plaza Z, Soriano V, Del Mar Gonzalez M, et al
J Antimicrob Chemother. 2011 Sep 27
 Abstract

Natural polymorphisms associated with resistance to new antivirals against HCV in newly
diagnosed HIV-HCV-coinfected patients.
Treviño A, de Mendoza C, Parra P, et al
Antivir Ther. 2011;16(3):413-6..
Abstract

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in
HIV/HCV-coinfected patients.
Trimoulet P, Belzunce C, Faure M,  et al
HIV Med. 2011 Mar 16.
Abstract

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic
hepatitis C.
Macías J, Neukam K, Portilla J, Iribarren JA,  et al
J Antimicrob Chemother. 2011 Mar 10
 Abstract

Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression
in HIV-HCV coinfection before and after antiretroviral therapy. 
Potter M, Odueyungbo A, Yang H, et al 
AIDS. 2010 May
 Abstract

Impact of Hepatitis C Virus Coinfection on HAART in HIV-Infected Individuals:
Multicentric Observation Cohort.
 Fuping G, Wei L, Yang H,  et al
J Acquir Immune Defic Syndr. 2010 Apr 26.
 Abstract

Impact of highly active antiretroviral therapy on hepatitis C virus protease
quasispecies diversity in HIV co-infected patients.
 Winters MA, Chary A, Eison R, et al
J Med Virol. 2010 Mar 24;82(5):791-798.
Abstract

Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
 Iorio A, Marchesini E, Awad T, Gluud LL.
 Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004888.
 Abstract

Sustained Virological Response after Early Antiviral Treatment of Acute Hepatitis C
Virus and HIV Coinfection.
 Schulze Zur Wiesch J, Pieper D, et al
Clin Infect Dis. 2009 Jul 6.
 Abstract

Case report: clearance of hepatitis C virus after changing the HAART regimen
in a patient infected with hepatitis C virus and the human immunodeficiency virus.
Endo T, Fujimoto K, Nishio M, et al  
J Med Virol. 2009 Jun;81(6):979-82.
 Abstract

HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C
virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time
of liver biopsy.
 Pascual-Pareja JF, Caminoa A, Larrauri C, et al
AIDS. 2009 May 15;23(8):971-5.
 Abstract

HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C
virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of
liver biopsy.
Pascual-Pareja JF, Caminoa A, Larrauri C, et al
AIDS. 2009 May 15;23(8):971-5
 Abstract

Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection.
 Ragni MV, Nalesnik MA, Schillo R, Dang Q.
Haemophilia. 2009 Mar;15(2):552-8
 Abstract
 
FULL-TEXT ARTICLE
 Is Antiretroviral Therapy Causing Long-Term Liver Damage? A Comparative Analysis of HIV-Mono-Infected
and HIV/Hepatitis C Co-Infected Cohorts.
 Moodie EE, Pant Pai N, Klein MB.
PLoS ONE. 2009;4(2):e4517.
Paper
 
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C,
and Human Immunodeficiency Virus Infection.
 Hofmann WP, Soriano V, Zeuzem S.
Handb Exp Pharmacol. 2009;189:321-346.
 Abstract
 
The influence of HCV coinfection on clinical, immunological and virological responses to HAART
in HIV-patients.
Carmo RA, Guimarães MD, Moura AS, et al
Braz J Infect Dis. 2008 Jun;12(3):173-9
 Abstract
 
Effect of Antiretroviral Therapy and Hepatitis C Co-infection on Changes in Lipid Levels in
HIV-Infected Patients 48 Weeks After Initiation of Therapy.
 Stapleton JT, Bennett K, Bosch RJ, et al 
HIV Clin Trials. 2007 Nov-Dec;8(6):429-36.
 Abstract
 
Case Report: Hepatitis C Virus Activation in HIV-Infected Patients Initiating Highly Active
Antiretroviral Therapy.
 Kim HN, Harrington RD, Shuhart MC, et al 
AIDS Patient Care STDS. 2007 Oct;21(10):718-23.
 Abstract
 
Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and
HIV-HCV infection.
 Cooper CL, Mills E.
Int J STD AIDS. 2007 Aug;18(8):546-50.
 Abstract
 
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency
virus-infected patients undergoing highly active antiretroviral therapy.
 Pineda JA, García-García JA, Aguilar-Guisado M, et al
Hepatology. 2007 Jul 20;
Abstract
 
Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy.
Zeitoun JD, Mallet V, Chaix ML, et al
J Clin Virol. 2007 Jul 18;
 Abstract
 
Early Initiation of Antiretroviral Therapy: The Current Best Way to Reduce Liver-Related
Deaths in HIV/Hepatitis C Virus-Coinfected Patients.
Shafran SD
 J Acquir Immune Defic Syndr. 2007 Jan 11;
 Abstract
 
Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV
and Hepatitis C Coinfection Using a Noninvasive Marker.
 Al-Mohri H, Murphy T, Lu Y,
J Acquir Immune Defic Syndr. 2007 Jan 4;
Abstract
 
Antiretroviral Medication Considerations for Individuals Coinfected with HIV and
Hepatitis C Virus.
 Lai AR, Tashima KT, Taylor LE.
AIDS Patient Care STDS. 2006 Oct;20(10):678-92.
 Abstract
 
Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection.
 Parsons TD, Tucker KA, Hall CD, et al 
AIDS. 2006 Aug 1;20(12):1591-5.
 Abstract
 
HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
 Verma S.
J Antimicrob Chemother. 2006 Jul 19;
Abstract
 
Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral
therapy.
 Sullivan PS, Hanson DL, Teshale EH, et al
AIDS. 2006 May 12;20(8):1171-1179.
 Abstract
 
Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at
an Haemophilia Unit during a decade.
Sauleda S, Martorell M, Esteban JI,
 Haemophilia. 2006 May;12(3):228-36
 Abstract
 
Impact of Hepatitis C Virus Coinfection on Response to Highly Active Antiretroviral Therapy
and Outcome in HIV-Infected Individuals: A Nationwide Cohort Study.
 Weis N, Lindhardt BO, Kronborg G, et al 
Clin Infect Dis. 2006 May 15;42(10):1481-7.
 Abstract
 
Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients.
Guitton E, Montastruc JL, Lapeyre-Mestre M;
Eur J Clin Pharmacol. 2006 Jan 17;
 Abstract
 
Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C
irus-coinfected patients?
 Verma S, Wang CH, Govindarajan S, et al 
Clin Infect Dis. 2006 Jan 15;42(2):262-70.
 Abstract
 
Immunologic Response to Antiretroviral Therapy in Hepatitis C Virus-Coinfected Adults in a
Population-Based HIV/AIDS Treatment Program.
Braitstein P, Zala C, Yip B, et al
 J Infect Dis. 2006 Jan 15;193(2):259-68.
 Abstract
 
Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection.
 Cooper C, Breau C, Laroche A, et al
HIV Med. 2006 Jan;7(1):32-7.
 Abstract
 
Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
 Brau N.
J Antimicrob Chemother. 2005 Nov 24;
Abstract
 
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression
using antiretroviral therapy.
 Brau N, Salvatore M, Rios-Bedoya CF, et al 
J Hepatol. 2005 Sep 20;
Abstract

Impact of Hepatitis C Virus on Immune Restoration in HIV-Infected Patients Who Start Highly
Active Antiretroviral Therapy: A Meta-analysis.
 Miller MF, Haley C, Koziel MJ, Rowley CF
Clin Infect Dis. 2005 Sep 1;41(5):713-20.
 Abstract
 
Effects of Hepatitis C Virus Coinfection on Survival in Veterans With HIV Treated With
Highly Active Antiretroviral Therapy.
 Backus LI, Phillips BR, Boothroyd DB
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):613-619.
Abstract
 
FULL-TEXT ARTICLE
 Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in
HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C, Lapadula G, Casari S, et al  
BMC Infect Dis. 2005 Jul 14;5(1):58
 Paper
 
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen:
increased incidence of stopping due to toxicity or patient/physician choice in patients with
hepatitis C coinfection.
Mocroft A, Phillips AN, Soriano V, et al
AIDS Res Hum Retroviruses. 2005 Jun;21(6):527-36.
 Abstract
 
Liver enzymes elevation after HAART in HIV-HCV co-infection.
 Servin-Abad L, Molina E, Baracco G, et al  
J Viral Hepat. 2005 Jul;12(4):429-34.
 Abstract
 
Influence of Liver Fibrosis on Highly Active Antiretroviral Therapy-Associated Hepatotoxicity
in Patient swith HIV and Hepatitis C Virus Coinfection.
 Aranzabal L, Casado JL, Moya J, et al
 Clin Infect Dis. 2005 Feb 15;40(4):588-93.
 Abstract
 
The effect of antiretroviral therapy on liver disease among adults with HIV and
hepatitis C coinfection.
 Mehta SH, Thomas DL, Torbenson M, et al 
Hepatology. 2004 Dec 23;41(1):123-131
 Abstract
 
Hepatitis C Virus Coinfection Increases Mortality in HIV-Infected Patients in the Highly
Active Antiretroviral Therapy Era: Data from the HIV Atlanta VA Cohort Study.
 Anderson KB, Guest JL, Rimland D, et al  
Clin Infect Dis. 2004 Nov 15;39(10):1507-13.
 Abstract
 
Hepatitis C Virus Coinfection Increases Mortality in HIV-Infected Patients in the Highly
Active Antiretroviral Therapy Era: Data from the HIV Atlanta VA Cohort Study.
 Anderson KB, Guest JL, Rimland D, et al  
Clin Infect Dis. 2004 Nov 15;39(10):1507-13.
 Abstract
 
The effect of hepatitis C on progression to AIDS before and after highly active
antiretroviral therapy.
 Dorrucci M, Valdarchi C, Suligoi B, et al 
AIDS. 2004 Nov 19;18(17):2313-2318.
 Abstract
 
HIV Infection, hepatitis C infection, and HAART: hard clinical choices.
 Kottilil S, Polis MA, Kovacs JA. et al 
JAMA. 2004 Jul 14;292(2):243-50.
 Abstract
 
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease
progression in the HIV-NAT cohort.
 Law WP, Duncombe CJ, Mahanontharit A,et al 
AIDS. 2004 May 21;18(8):1169-1177.
 Abstract
 
Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
 Bonacini M.
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S104-8.
 Abstract
 
Impact of highly active antiretroviral therapy on the spectrum of liver disease in hcv-hiv
coinfection.
 Sterling RK, Wilson MS, Sanyal AJ, et al 
Clin Gastroenterol Hepatol. 2004 May;2(5):432-9
 Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C:
harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
 AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
 
Antiretroviral Therapy in Patients with Hepatitis and HIV: Weighing Risks and Benefits.
 Powderly WG.  
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S109-13.
 Abstract
 
The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune
response.
 Herrero-Martinez E, Sabin CA, et al
J Med Virol. 2004 Feb;72(2):187-93
 Abstract

Impaired Recovery of CD4+ Cell Counts Following Highly Active Antiretroviral Therapy in
Drug-Naive Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
 Macias J, Pineda JA, Lozano F, et al
Eur J Clin Microbiol Infect Dis. 2003 Oct 23
Abstract
 
Effect of HAART on HCV viral load in the first three years of follow-up
 Tornero C, Gimeno C, Igual R, et al 
Drug Alcohol Depend. 2003 Oct 24;72(1):13-21
 Abstract
 
The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active
Antiretroviral Therapy.
Klein MB, Lalonde RG, Suissa S.
Acquir Immune Defic Syndr. 2003 Jul 1;33(3):365-372.
Abstract

Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus
quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.
 Babik JM, Holodniy M.
J Virol 2003 Feb;77(3):1940-50
 Abstract

Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA
levels in human immunodeficiency virus and HCV coinfection.
Cooper CL, Cameron DW.
Clin Infect Dis 2002 Oct 1;35(7):873-9
 Abstract

  

     Conference Reports, Abstracts, and Posters

 
POSTER
Initiation of ART in the Modern Era Is Associated with Decreased Risk of Hepatotoxicity in HIV/HCV Co-infected Patients
M Hull W Zhang, B Yip, et al
 (19 CROI)
PDF Poster     Abstract
 
POSTER
Cumulative Exposure to ARV Drugs Leads to Progressive Hepatic Steatosis among HIV/HCV-co-infected Patients
J Macias, J Berenguer, M Japón,  et al
 (19 CROI)
PDF Poster     Abstract

POSTER
Interruption of Antiretroviral Therapy (ART) is Associated with Progression of Liver Fibrosis in
HIV/HCV Co-infected Adults
 J Thorpe, S Saeed, E Moodie, et al
(17 CROI)
PDF Poster     Abstract
 

POSTER
 HCV Stimulates HIV Immune Activation in HIV/HCV Co-infected Subjects on HAART
H Rempel, B Sun, A Monto, et al
(17th CROI)
PDF Poster     Abstract
 
POSTER
 Response to Antiretroviral Therapy (ART) of HIV/HCV Co-infected Patients at Outpatient Clinics
in Vietnam
D Nguyen, N Do, L Cosimi, et al
 (17 CROI)
PDF Poster     Abstract
 
POSTER
 Does Treatment Interruption within the Strategies for the Management of ART Trial Lead to
Changes in HCV Load in HIV/HCV-co-infected Patients?
J Rockstroh and the INSIGHT SMART Study Group
 (16t CROI)
PDF Poster     Abstract
 

Impact of different ART regimens on efficacy and safety of standard HCV treatment in
HIV/HCV co-infected patients
 Khaykin P, Vogel M, Voigt E, Rockstroh J, et al
 (4th IAS Conference)
 Abstract
 
Factors Associated with High HCV Viral Load in HIV/HCV Co-infected Patients: Is There a
Different Effect between PI and Non-PI-based ART?
 F Bani-Sadr, I Goderel, P Morand, et al
 (14 CROI)
 Abstract
 
POSTER
 Progression after Initiating ART Combination Therapy in HIV/HCV-co-infected Patients According
to Different Baseline CD4+ Cell Count Strata
 F Dronda, J Zamora, C Quereda, et al
(14 CROI)
 PDF Poster   Abstract
 
POSTER
 HAART Reduces the Fibrosis Progression Rate and the Development of Bridging Fibrosis and
Cirrhosis in HIV/HCV-co-infected Patients
 S Resino, Juan Berenguer, P Miralles,. et al
 (14 CROI)
 PDF Poster   Abstract
 
POSTER
 Clinical Progression of Hepatitis C Virus-related Chronic Liver Disease in HIV-infected Patients
Undergoing HAART
 JA García-García, M Aguilar-Guisado, M Ríos-Villegas, et al
 (14 CROI)
 PDF Poster   Abstract

POSTER
 Pharmacokinetics of Boosted PI and NNRTI in HCV/HIV-co-infected Patients
 D Breilh, S Guinguené, V de Lédinghen, et al
(14 CROI)
 PDF Poster   Abstract
 
The Influence of Genotype 3 Hepatitis C Co-Infection on Liver Enzyme Elevations in HIV-
Infected Patients after Commencement of a New HAART: Results from the MASTER-
EPOKA Cohort   
 C. TORTI, M. PUOTI , G. LAPADULA , et al
(45 ICAAC)
Abstract
 
Risk of Haart-Associated Hepatotoxicity in HIV/HCV Co-Infected Patients with Cirrhosis
 L. ARANZABAL, J.L. CASADO, J. MOYA, et al
(45 ICAAC)
Abstract
 
Hepatotoxicity in HIV-Infected Patients Starting HAART
L. ARANZABAL, J L. CASADO, P. DOMINGO, et al 
(45 ICAAC)
Abstract
 
POSTER
Virologic and immunologic response to antiretroviral therapy among HIV patients
co-infected with hepatitis C virus (HCV) - analysis of a 6,401 HIV patient cohort.
BJ Cowling, CA Donnelly, AC Ghani et al  
(XV International AIDS Conference)
 PDF Poster    Abstract

HAART-associated Hepatotoxicity in HIV/HCV Co-infected Patients: Correlation with
Liver Histologic Stage
 J Moya, L Aranzabal, J L Casado, et al  
(11 CROI)
 Abstract
Abacavir
     
     Journal Papers, Abstracts, and Commentaries
 
  Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with
pegylated interferon and weight-adjusted ribavirin.
 Laufer N, Laguno M, Perez I, et al  
Antivir Ther. 2008;13(7):953-7
 Abstract
Atazanavir
     
     Journal Papers, Abstracts, and Commentaries
 
 
The use of atazanavir in hiv infected patients with liver cirrhosis: lack of hepatotoxicity and
no significant changes in bilirubin values or meld score.
Rodriguez JM, Hermida JM, Casado JL, et al
AIDS. 2011 Mar 17.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Short-Term Effect of Ritonavir-Boosted Atazanavir in Hepatitis B and/or C Co-infected,
Treatment-Experienced HIV Patients.
 Pérez-Elías MJ, Gatell JM, Flores J, et al
HIV Clin Trials. 2009 Jul-Aug;10(4):269-75|
 Abstract

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following
initiation of pegylated-interferon and ribavirin.
 Rodríguez-Nóvoa S, Morello   
 AIDS. 2008 Nov 30;22(18):2535-7
 Abstract

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients
co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
 Pineda JA, Santos J, Rivero A, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract
 
    Conference Reports, Abstracts, and Posters
 
 
Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)
 Absalon J, Thal G, Thiry A, Yang R, et al 
(Ninth International Congress on Drug Therapy in HIV Infection)
 Abstract

Pharmacokinetics of atazanavir in HIV-1-HCV co-infected patients
 Gatti F, Nasta P, Matti A, et al
(4th IAS Conference)
 Abstract
Darunavir
     
     Journal Papers, Abstracts, and Commentaries
 
  Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected
and HIV monoinfected patients.
 Morsica G, Bianchi G, Bagaglio S,  et al
New Microbiol. 2011 Jul;34(3):317-21
 Abstract

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in
Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3.
Rachlis A, Clotet B, Baxter J, et al
HIV Clin Trials. 2007 Jul-Aug;8(4):213-20.
 Abstract
 
    Conference Reports, Abstracts, and Posters
 
  Comparison of liver toxicity in HIV/HCV coinfected and HIV monoinfected patients during 72 weeks
ART including darunavir/ritonavir
G. Morsica, G. Bianchi, S. Bagaglio, et al
(XVIII IAC)
 Abstract
   
  Hepatic safety of darunavir 600/100 in HCV coinfected patients with HAART experience
M.A. von Wichmann, M. Saenz-Cuesta, K. Aguirrebengoa, et al
(XVIII IAC)
 Abstract
Didanosine
 

     Journal Papers, Abstracts, and Commentaries

 
Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy
in HIV/HCV Co-infected Patients.
Vispo E, Maida I, Barreiro P, et al 
HIV Clin Trials. 2008 Jan 1;9(6):440-444
 Abstract
 
Nucleoside analogues and mitochondrial toxicity.
 Fleischer R, Boxwell D, Sherman KE. 
Clin Infect Dis. 2004 Apr 15;38(8):e79-80
 Abstract

Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity
against HIV-1 and hepatitis C virus.
 Klein MB, Campeol N, Lalonde RG, et al.  
 AIDS 2003 May 2;17(7):1001-1008
 Abstract

  
Efavirenz
     
     Journal Papers, Abstracts, and Commentaries
 
 
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
 Pineda JA, Neukam K, Mallolas J,  et al
J Infect. 2011 Nov 25.
Abstract

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease
inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
 Neukam K, Mira JA, Ruiz-Morales J, et al
J Antimicrob Chemother. 2011 Sep 7.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic
hepatitis B or C.
 Meynard JL, Lacombe K, Poirier JM,  et al
J Antimicrob Chemother. 2009 Jan 23.
 Abstract

Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV
-Coinfected Patients.
 Quereda C, Corral I, Moreno A, Pérez-Elías MJ,
 J Acquir Immune Defic Syndr. 2008 Jul 23.
Abstract

Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM
of EFV.
 Katsounas A, Frank A, Klinker H, Langmann P. 
Eur J Med Res. 2007 Aug 16;12(8):331-6
 Abstract
Fosamprenavir
     
     Journal Papers, Abstracts, and Commentaries
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a
HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
Perrella A, Sbreglia C, D'Antonio A, et al 
Clin Microbiol Infect. 2009 Jul 20.
 Abstract

Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with
mild-moderate liver impairment resulting from HCV-related cirrhosis.
 Gatti F, Nasta P, Loregian A, Puoti M, et al 
J Antimicrob Chemother. 2009 Jan 16.
 Abstract

Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir
and correlation with plasma levels.
Spagnuolo V, Gentilini G, De Bona A, et al
New Microbiol. 2007 Jul;30(3):279-82.
 Abstract
Lopinavir
 

     Journal Papers, Abstracts, and Commentaries

 
Safety and Pharmacokinetics of Lopinavir in HIV/HCV Coinfected Patients with Advanced Liver Disease.
Casado JL, Del Palacio M, Moya J, et al
HIV Clin Trials. 2011 Sep-Oct;12(5):235-43.
 Abstract

Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough
concentrations in HIV-infected patients.
Calza L, Mosca L, Pocaterra D, et al
Eur J Clin Pharmacol. 2010 Sep 28
 Abstract

Evolution of HIV and HCV coinfected children receiving long-term lopinavir/ritonavir-based
antiretroviral therapy.
 Larrú B, Resino S, Bellón JM, et al
Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):426-9.
 Abstract
 
Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients With or Without Cirrhosis.
 Micheli V, Regazzi M, Dickinson L,
Ther Drug Monit. 2008 Jun;30(3):306-313
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients
without Liver Function Impairment : Influence of Liver Fibrosis.
 Molto J, Valle M, Blanco A, Negredo E, et al
Clin Pharmacokinet. 2007;46(1):85-92.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus-Coinfected Subjects With
Hepatic Impairment.
Peng JZ, Pulido F, Causemaker SJ, et al
J Clin Pharmacol. 2006 Mar;46(3):265-74.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with
protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected
patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE, Shire NJ, Cernohous P, et al
Clin Infect Dis. 2005 Oct 15;41(8):1186-95.
 Abstract

    Conference Reports, Abstracts, and Posters

  POSTER
No effect of HCV infection on virological response 96 weeks after simplification to lopinavir/ritonavir (LPV/r) monotherapy (MT) in the OK04 trial
F. Pulido, J. Arribas, OK04 Study Group
(6th IAS Conference)
 Poster      Abstract

POSTER
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV coinfected patients starting anti-HCV treatment: final results of a
randomised, proof-of- principle clinical trial (KAMON 2 Study)
H. Hasson, L. Galli, G. Gallotta
 (6th IAS Conference)
 Poster      Abstract

POSTER
 Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/r
or Nelfinavir-based Therapy
KE Sherman, NJ Shire, P Cernohous, et al.
 1l CROI
 PDF Poster
Maraviroc
 
     Journal Papers, Abstracts, and Commentaries
 
  Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the
Maraviroc Expanded Access Program.
 Lazzarin A, Than S, Valluri SR, et al
HIV Clin Trials. 2012 Mar-Apr;13(2):83-9
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in
HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
 Macías J, Viloria MM, Rivero A, et al 
Eur J Clin Microbiol Infect Dis. 2012 Jan 19.
 Abstracts

     Conference Reports, Abstracts, and Posters

Maraviroc (MVC) reduces liver stiffness (LS) in HIV-hepatitis C (HCV) co-infected patients
 P. Nasta, F. Gatti, F. Borghi,  et al
(6th IAS Conference)
Abstract
Nelfinavir
 

     Journal Papers, Abstracts, and Commentaries

  Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with
protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected
patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE, Shire NJ, Cernohous P, et al
Clin Infect Dis. 2005 Oct 15;41(8):1186-95.
 Abstract

     Conference Reports, Abstracts, and Posters

  POSTER
 Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/r
or Nelfinavir-based Therapy
KE Sherman, NJ Shire, P Cernohous, et al.
(1l CROI)
 PDF Poster
Nevirapine
 

   Journal Papers, Abstracts, and Commentaries

Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in
Patients with HIV and Hepatitis C Virus Coinfection.
 Berenguer J, Bellón JM, Miralles P, et al  
Clin Infect Dis. 2008 Jan 1;46(1):137-43.
 Abstract
 
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis
C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E, Gutiérrez S, Jahnke N, et al
 AIDS. 2007 Jul 31;21(12):1561-156
 Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C:
harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
Raltegravir
 

     Conference Reports, Abstracts, and Posters

POSTER
Multiple-dose Pharmacokinetics of Raltegravir in Patients Co-infected with HIV/HCV with and without
Advanced (Child-Pugh grade C) Hepatic Cirrhosis
B Hernandez-Novoa, A Moreno, M Perez-Elias, et al
 (19 CROI)
PDF Poster     Abstract

POSTER
 Hepatic Safety and Efficacy of Raltegravir in Patients Co-infected with HIV and HBV or HCV
 J Rockstroh, H Teppler, J Zhao, et al
 (17 CROI)
PDF Poster     Abstract
Ritonavir
 
   Journal Papers, Abstracts, and Commentaries
 
  Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease
inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
 Neukam K, Mira JA, Ruiz-Morales J, et al
J Antimicrob Chemother. 2011 Sep 7.
Abstract
 

 

Stavudine
 

     Conference Reports, Abstracts, and Posters

Population Prevalence of Hepatic Steatosis among Antiretroviral-experienced HCV/HIV
Co-infected Adults with and without Stavudine Exposure
 M Sulkowski, S Mehta, R Moore, M Torbenson, et al
 (15th CROI)
Abstract
Tenofovir
 
   Journal Papers, Abstracts, and Commentaries
 
  Role of tenofovir in HIV and hepatitis C virus coinfection.
Tuma P, Vispo E, Barreiro P, Soriano V.
Enferm Infecc Microbiol Clin. 2008 Jun;26(Supl.8):31-37
 Abstract
 

     Conference Reports, Abstracts, and Posters

Renal toxicity in HIV/Hepatitis C co-infected individuals exposed to tenofovir and/or Ribavarin
Jones R., Bower M., Mandalia S., et al
(XVI  International AIDS Conference)
Abstract
Tipranavir
 

     Journal Papers, Abstracts, and Commentaries

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations:
effect of hepatitis virus co-infection and pre-existing fibrosis.
Macías J, Orihuela F, Rivero A, et al
 J Antimicrob Chemother. 2008 Oct 24.
Abstract
Zidovudine
 

     Journal Papers, Abstracts, and Commentaries

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during
HCV treatment in HIV-infected persons.
Alvarez D, Dieterich DT, Brau N, et al
 J Viral Hepat. 2006 Oct;13(10):683-9
 Abstract

HIV/HCV Main Page Main New/Newsworthy  Home Page

Antiretroviral Drugs